Suchergebnisse - "Kirchgesner, Julien"

PubPharm (8)

1

Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease

enthalten in: Gut | 2022

von Kirchgesner, J. | Desai, R. | Schneeweiss, M. | +3

2

Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2022

von Kirchgesner, J. | Desai, R. | Beaugerie, L. | +2

CommentIn: Clin Gastroenterol Hepatol. 2022 Feb;20(2):e28-e30. - PMID 34022455

3

Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease

enthalten in: Inflammatory bowel diseases | 2022

von Alric, H. | Amiot, A. | Kirchgesner, J. | +6

4

Calibrating Real-World Evidence Studies Against Randomized Trials : Treatment Effectiveness of Infliximab in Crohn's Disease

enthalten in: Clinical pharmacology and therapeutics | 2022

von Kirchgesner, J. | Desai, R. | Beaugerie, L. | +2

5

Ustekinumab for Perianal Crohn's Disease : The BioLAP Multicenter Study From the GETAID

enthalten in: The American journal of gastroenterology | 2020

von Chapuis-Biron, C. | Kirchgesner, J. | Pariente, B. | +23

6

The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2020

von Kassouri, L. | Amiot, A. | Kirchgesner, J. | +6

7

Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation : A Multicentre Cohort Study

enthalten in: Journal of Crohn's & colitis | 2020

von Martin, A. | Nachury, M. | Peyrin-Biroulet, L. | +62

8

Efficacy and safety of golimumab in Crohn's disease : a French national retrospective study

enthalten in: Alimentary pharmacology & therapeutics | 2017

von Martineau, C. | Flourié, B. | Wils, P. | +44

CommentIn: Aliment Pharmacol Ther. 2020 Jun;51(12):1449-1451. - PMID 32445531

1
[1]